Because REMS® is radiation-free and produces both density and quality data, it is clinically appropriate for populations that historically have had limited bone assessment options.
The only bone assessment safe during pregnancy. Establishes a maternal baseline before the largest bone draw of a woman's life.
Bone loss accelerates significantly during the menopause transition. REMS® catches it earlier than standard screening protocols allow.
Rapid weight loss is associated with measurable bone density decline. A baseline assessment protects what the scale doesn't show.
Bone density alone underestimates fracture risk in diabetic patients. REMS® bone quality assessment is more accurate for this population.
Treatment-related bone loss is significant. Radiation-free monitoring is appropriate for patients already exposed to therapeutic radiation.
Glucocorticoids, proton pump inhibitors, aromatase inhibitors, and other medications affect bone over time. REMS® allows safe repeated monitoring.
Pre-operative bone assessment for joint replacement and spine surgery. Helps surgical teams plan and manage post-operative outcomes.
Performance-oriented individuals tracking bone health alongside training load. Repeated safe monitoring supports long-term planning.
Establishing a baseline before peak bone loss begins. The earlier the picture is known, the more can be done about it.
Public booking opens Summer 2026. Get on the early list, or if you're a provider or organization, bring REMS® to the people you serve.
